Sam Seidu MBChB

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6384273/publications.pdf

Version: 2024-02-01

87 papers 2,806 citations

201385 27 h-index 205818 48 g-index

95 all docs 95 docs citations 95 times ranked 4747 citing authors

#	Article	IF	CITATIONS
1	Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 965-967.	1.8	390
2	Prevalence of coâ€morbidities and their association with mortality in patients with <scp>COVID</scp> â€19: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1915-1924.	2.2	320
3	Association Between Adherence to Pharmacotherapy and Outcomes in Type 2 Diabetes: A Meta-analysis. Diabetes Care, 2017, 40, 1588-1596.	4.3	143
4	Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881984469.	1.4	100
5	Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematology,the, 2017, 4, e83-e93.	2.2	91
6	The impact of obesity on severe disease and mortality in people with SARSâ€CoVâ€2: A systematic review and metaâ€analysis. Endocrinology, Diabetes and Metabolism, 2021, 4, e00176.	1.0	87
7	SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. Primary Care Diabetes, 2018, 12, 265-283.	0.9	62
8	Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence. European Journal of Epidemiology, 2017, 32, 657-667.	2.5	59
9	Relationship of cardiometabolic parameters in non-smokers, current smokers, and quitters in diabetes: a systematic review and meta-analysis. Cardiovascular Diabetology, 2016, 15, 158.	2.7	58
10	Comorbid depression and risk of cardiac events and cardiac mortality in people with diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2019, 156, 107816.	1.1	56
11	Deintensification in older patients with type 2 diabetes: A systematic review of approaches, rates and outcomes. Diabetes, Obesity and Metabolism, 2019, 21, 1668-1679.	2.2	56
12	Physical activity and risk of venous thromboembolism: systematic review and meta-analysis of prospective cohort studies. European Journal of Epidemiology, 2020, 35, 431-442.	2.5	56
13	Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. European Heart Journal, 2017, 38, 1608-1612.	1.0	52
14	Older people with Type 2 diabetes, including those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea or insulin therapies. Diabetic Medicine, 2017, 34, 1219-1227.	1.2	47
15	Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovascular Diabetology, 2019, 18, 70.	2.7	46
16	Aspirin for primary prevention of cardiovascular and allâ€cause mortality events in diabetes: updated metaâ€analysis of randomized controlled trials. Diabetic Medicine, 2017, 34, 316-327.	1.2	44
17	Obesity, walking pace and risk of severe COVID-19 and mortality: analysis of UK Biobank. International Journal of Obesity, 2021, 45, 1155-1159.	1.6	43
18	Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K BMC Infectious Diseases, 2021, 21, 908.	1.3	41

#	Article	IF	CITATIONS
19	Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews. Diabetes Care, 2021, 44, 2790-2811.	4.3	41
20	Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2018, 20, 2169-2178.	2.2	40
21	A systematic review of interventions targeting primary care or community based professionals on cardio-metabolic risk factor control in people with diabetes. Diabetes Research and Clinical Practice, 2016, 113, 1-13.	1.1	38
22	Effects of glucoseâ€lowering and multifactorial interventions on cardiovascular and mortality outcomes: a metaâ€analysis of randomized control trials. Diabetic Medicine, 2016, 33, 280-289.	1.2	36
23	Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine, 2021, 32, 100739.	3.2	36
24	Plasma calprotectin and risk of cardiovascular disease: Findings from the PREVEND prospective cohort study. Atherosclerosis, 2018, 275, 205-213.	0.4	31
25	Depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence. Annals of Medicine, 2018, 50, 529-537.	1.5	31
26	Cardiovascular efficacy and safety of sodiumâ€glucose coâ€transporterâ€2 inhibitors and glucagonâ€like peptideâ€1 receptor agonists: a systematic review and network metaâ€analysis. Diabetic Medicine, 2019, 36, 444-452.	1.2	30
27	Pandemic threatens primary care for long term conditions. BMJ, The, 2020, 371, m3793.	3.0	30
28	Priorities of patients with multimorbidity and of clinicians regarding treatment and health outcomes: a systematic mixed studies review. BMJ Open, 2020, 10, e033445.	0.8	30
29	Therapeutic Inertia and the Legacy of Dysglycemia on the Microvascular and Macrovascular Complications of Diabetes. Diabetes Care, 2019, 42, 349-351.	4.3	29
30	Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people. Primary Care Diabetes, 2019, 13, 330-352.	0.9	28
31	Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetologica, 2019, 56, 839-850.	1.2	28
32	A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. Primary Care Diabetes, 2021, 15, 31-51.	0.9	27
33	Indirect impact of the COVID-19 pandemic on hospitalisations for cardiometabolic conditions and their management: A systematic review. Primary Care Diabetes, 2021, 15, 653-681.	0.9	27
34	Serum albumin, cardiometabolic and other adverse outcomes: systematic review and meta-analyses of 48 published observational cohort studies involving 1,492,237 participants. Scandinavian Cardiovascular Journal, 2020, 54, 280-293.	0.4	26
35	Prevalence and characteristics in coding, classification and diagnosis of diabetes in primary care. Postgraduate Medical Journal, 2014, 90, 13-17.	0.9	24
36	Inverse association between serum albumin and future risk of venous thromboembolism: interrelationship with high sensitivity C-reactive protein. Annals of Medicine, 2018, 50, 240-248.	1.5	23

#	Article	IF	CITATIONS
37	Online patient education interventions in type 2 diabetes or cardiovascular disease: A systematic review of systematic reviews. Primary Care Diabetes, 2019, 13, 16-27.	0.9	23
38	The right place for Sulphonylureas today: Part of †Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitus'. Diabetes Research and Clinical Practice, 2019, 157, 107836.	1.1	23
39	Integrated primary care: is this the solution to the diabetes epidemic?. Diabetic Medicine, 2017, 34, 748-750.	1.2	21
40	Self-knowledge of HbA1c in people with Type 2 Diabetes Mellitus and its association with glycaemic control. Primary Care Diabetes, 2017, 11, 414-420.	0.9	21
41	Physical activity and risk of atrial fibrillation in the general population: meta-analysis of 23 cohort studies involving about 2 million participants. European Journal of Epidemiology, 2021, 36, 259-274.	2.5	21
42	Non-adherence to diabetes guidelines in primary care – The enemy of evidence-based practice. Diabetes Research and Clinical Practice, 2012, 95, 301-302.	1.1	19
43	Physical activity reduces the risk of pneumonia: systematic review and meta-analysis of 10 prospective studies involving 1,044,492 participants. GeroScience, 2022, 44, 519-532.	2.1	18
44	Handgrip strengthâ€"a risk indicator for future fractures in the general population: findings from a prospective study and meta-analysis of 19 prospective cohort studies. GeroScience, 2021, 43, 869-880.	2.1	17
45	Biochemical Urine Testing of Adherence to Cardiovascular Medications Reveals High Rates of Nonadherence in People Attending Their Annual Review for Type 2 Diabetes. Diabetes Care, 2019, 42, 1132-1135.	4.3	16
46	Clinical update: The important role of dual kidney function testing (ACR and eGFR) in primary care: Identification of risk and management in type 2 diabetes. Primary Care Diabetes, 2020, 14, 370-375.	0.9	16
47	The importance of physical activity in management of type 2 diabetes and COVID-19. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110546.	1.4	16
48	COVID-19 vaccine uptake and hesitancy opinions from frontline health care and social care workers: Survey data from 37 countries. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102361.	1.8	16
49	The impact of the COVID pandemic on primary care diabetes services in the UK: A cross-sectional national survey of views of health professionals delivering diabetes care. Primary Care Diabetes, 2022, 16, 257-263.	0.9	16
50	Evaluating the impact of an enhanced primary care diabetes service on diabetes outcomes: A before–after study. Primary Care Diabetes, 2017, 11, 171-177.	0.9	15
51	Prevalence and progression of diabetic nephropathy in South Asian, white European and African Caribbean people with type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2019, 21, 658-673.	2.2	15
52	2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Primary Care Diabetes, 2022, 16, 223-244.	0.9	15
53	Therapeutic inertia amongst general practitioners with interest in diabetes. Primary Care Diabetes, 2018, 12, 87-91.	0.9	14
54	Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? A network meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis, 2018, 271, 223-231.	0.4	13

#	Article	IF	CITATIONS
55	Comparative effectiveness of gliclazide modified release versus sitagliptin as secondâ€line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2417-2426.	2.2	13
56	Association of circulating osteocalcin with cardiovascular disease and intermediate cardiovascular phenotypes: systematic review and meta-analysis. Scandinavian Cardiovascular Journal, 2019, 53, 286-295.	0.4	12
57	Benefits and harms of sodiumâ€glucose coâ€transporterâ€2 inhibitors (SGLT2â€I) and renin–angiotensin–aldosterone system inhibitors (RAASâ€I) versus SGLT2â€Is alone in patients with type 2 diabetes: A systematic review and metaâ€analysis of randomized controlled trials. Endocrinology, Diabetes and Metabolism, 2022, 5, e00303.	1.0	12
58	Improving diabetes care among patients with severe mental illness: A systematic review of the effect of interventions. Primary Care Diabetes, 2018, 12, 289-304.	0.9	11
59	Influence of sociodemographic characteristics on the preferred format of health education delivery in individuals with type 2 diabetes mellitus and or cardiovascular disease: a questionnaire study. Diabetic Medicine, 2020, 37, 982-990.	1.2	11
60	<p>De-Intensification Of Blood Glucose Lowering Medication In People Identified As Being Over-Treated: A Mixed Methods Study</p> . Patient Preference and Adherence, 2019, Volume 13, 1775-1783.	0.8	9
61	Serum Albumin and Future Risk of Hip, Humeral, and Wrist Fractures in Caucasian Men: New Findings from a Prospective Cohort Study. Medical Principles and Practice, 2019, 28, 401-409.	1.1	9
62	Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (<scp>SARSâ€CoV</scp> â€2 or <scp>COVID</scp> â€19). Diabetes, Obesity and Metabolism, 2020, 22, 1942-1945.	2.2	9
63	Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?. Primary Care Diabetes, 2021, 15, 59-68.	0.9	9
64	Plasma neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease: Findings from the PREVEND prospective cohort study. Clinica Chimica Acta, 2018, 486, 66-75.	0.5	8
65	Effect of pragmatic versus explanatory interventions on medication adherence in people with cardiometabolic conditions: a systematic review and meta-analysis. BMJ Open, 2020, 10, e036575.	0.8	8
66	Statins and risk of thromboembolism: A meta-regression to disentangle the efficacy-to-effectiveness gap using observational and trial evidence. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1023-1029.	1.1	7
67	Postpartum monitoring of women with a history of gestational diabetes â€" A cross-sectional study of an inner-city population. Primary Care Diabetes, 2019, 13, 376-379.	0.9	7
68	Does the presence of diabetes mellitus confer an increased risk of stroke in patients with atrial fibrillation on direct oral anticoagulants? A systematic review and meta-analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1725-1733.	1.8	7
69	Ethnic, social and multimorbidity disparities in therapeutic inertia: A <scp>UK</scp> primary care observational study in patients newly diagnosed with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 2437-2445.	2.2	7
70	COVID-19, ethnicity and cardiometabolic disease self-management in UK primary care. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 2241-2243.	1.8	5
71	Cardiovascular outcome trials of glucose-lowering therapies. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 237-249.	0.7	5
72	Should sodiumâ€glucose coâ€transporterâ€2 inhibitors be considered as firstâ€line oral therapy for people with type 2 diabetes?. Diabetes, Obesity and Metabolism, 2019, 21, 207-209.	2.2	4

#	Article	IF	CITATIONS
73	Impact on guidelines: The general practitioner point of view. Diabetes Research and Clinical Practice, 2020, 166, 108091.	1.1	4
74	Physical Activity after Cardiac EventS (PACES): a group education programme with subsequent text message support designed to increase physical activity in individuals with diagnosed coronary heart disease: a randomised controlled trial. Open Heart, 2021, 8, e001351.	0.9	4
75	Diabetes research in primary care: fiction, reality or essential?. Diabetic Medicine, 2018, 35, 832-834.	1.2	3
76	A cost comparison of an enhanced primary care diabetes service and standard care. Primary Care Diabetes, 2021, 15, 601-606.	0.9	3
77	De-intensification in older people with type 2 diabetes: why, when and for whom?. The Lancet Healthy Longevity, 2021, 2, e531-e532.	2.0	3
78	Consultation rates in people with type 2 diabetes with and without vascular complications: a retrospective analysis of 141,328 adults in England. Cardiovascular Diabetology, 2022, 21, 8.	2.7	3
79	Response to commentary by Rhew and colleagues on: Depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence. Annals of Medicine, 2019, 51, 99-100.	1.5	2
80	Effectiveness of the Transformation model, a model of care that integrates diabetes services across primary, secondary and community care: A retrospective study. Diabetic Medicine, 2021, 38, e14504.	1.2	2
81	Dashboards to reduce inappropriate prescribing of metformin and aspirin: A quality assurance programme in a primary care sentinel network. Primary Care Diabetes, 2021, 15, 1075-1079.	0.9	2
82	Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. Diabetes Therapy, 2022, 13, 889-911.	1.2	2
83	Further case for cohort studies of non-communicable diseases in sub-Saharan Africa. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1048-1049.	1.1	1
84	Managing vascular risk factors among obese quitters with diabetes: how intensive lifestyle intervention and novel pharmacotherapy can work in concert?. British Journal of Diabetes, 2017, 17, 19.	0.1	0
85	Gestational Diabetes Mellitus. , 2020, , 479-492.		0
86	OUP accepted manuscript. Journal of Public Health, 2022, , .	1.0	0
87	Cardiovascular and renal outcomes of initial combination therapy with glucoseâ€lowering agents versus a stepwise approach in newly diagnosed or treatmentâ€naĀ⁻ve type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1469-1482.	2.2	0